Biostax P/B

Mitä Biostax tekee? Biostax Corp, trading under the ticker BTAX with ISIN US45252A3059, is a U.S.-based biotechnology company headquartered in Winter Park. The company went public via an IPO on July 16, 2001. Biostax Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is https://www.biostaxcorp.com/. Biostax Corp has established partnerships in the fields of autoimmunity and immune restoration, focusing on solutions for conditions including autoimmunity, chronic inflammation, infection, and cancer. The company's subsidiary, BiostaxRx, is dedicated to the treatment of inflammaging disease. Biostax Corp's product portfolio includes Londonal, JKB-122, and Low Dose Naltrexone. Londonal is described as a once-a-day immune system regulator for managing HIV/AIDS. JKB-122 is a therapy targeting Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD), and Nonalcoholic steatohepatitis (NASH), with properties that are anti-fibrotic, immune modulating, and/or anti-inflammatory. The company's operations and product descriptions are based on the information provided in the source description, which is treated as untrusted. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are included in the provided facts. Biostax on yksi Eurpooliin suosituimmista yhtiöistä.